PCVX Q4 2024 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$162M

Net Income

-$137M

EPS (Diluted)

$-1.12

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$111M

Free Cash Flow

-$141M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$3.5B

Total Liabilities

$205M

Stockholders' Equity

$3.3B

Cash & Equivalents

$388M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$162M	-$197M	+17.5%
Net Income	-$137M	-$181M	+24.2%